The Moderna vaccine is proving to be 94.5% effective against Coronavirus. If the vaccine continues to prove to be effective, vaccinations could begin distribution in the last half of December.
“It was one of the greatest moments in my life and my career. It is absolutely amazing to be able to develop this vaccine and see the ability to prevent symptomatic disease with such high efficacy,” said Dr. Tal Zacks, Moderna’s chief medical officer.
The vaccine is the second one to have a high success rate in the U.S. An initial trial was conducted with 30,000 participants that concluded in a 94.5% success rate.
Moderna says it expects to have 20 million doses for the U.S. right away. They announced today that they have met the primary endpoint of the first interim analysis.
For more information on COVID-19 and current events, visit CIMA Law Group and CIMA Blog.
